

Title	Improving the Identification and Management of Patients with Familial Hypercholesterolaemia and Patients with Cardiovascular Disease and Primary Hypercholesterolaemia / Mixed Dyslipidaemia in Leicestershire and Rutland.
Organisations Involved	University Hospitals of Leicester NHS Trust and Amgen Limited.
Joint Working Project Description	<p>This Project was agreed as part of the Accelerated Access Collaborative (AAC), which was formed to bring industry, government and the NHS together to remove barriers to uptake of innovation products from 7 high-potential technology areas, so that NHS patients can have faster access to certain products that can transform care.</p> <p>PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products to increase patient access and remove barriers across the health innovation landscape.</p> <p>Funding was made available through the Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practice and to improve equality of access to these products.</p> <p>The PTF, in relation to PCSK9 inhibitors, combined funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers.</p> <p>19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for funding and 6 were selected, including University Hospitals of Leicester NHS Trust.</p> <p>The overall aim of University Hospitals of Leicester NHS Trust working in partnership with primary care and Amgen / Sanofi is to improve the identification and management of patients with familial hypercholesterolaemia (FH) and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. Improved cholesterol management will reduce the cardiovascular disease risk for these patients.</p> <p>UHL employed a clinical pharmacist or nurse with admin support to work on the project and to achieve the following objectives:</p> <ul style="list-style-type: none"> • Undertake a systematic search of GP records to identify patients with potential FH and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. • Clinical pharmacist / nurse led review of high-risk patients in primary care to optimise cholesterol management. • Identification of patients with elevated LDL-C despite maximal lipid lowering medications and referral of these patients to the lipid clinic to review treatment options to improve LDL-C.
Expected Outcomes	Predicted Benefits for Patients

	<ul style="list-style-type: none"> • Increased diagnosis rate of FH and improved management of primary hypercholesterolaemia and mixed dyslipidaemia. • These patients can be initiated and / or treated with appropriate doses of cholesterol lowering medicines according to local guidelines which will lower their risk of cardiovascular disease / event (stroke, myocardial infarction or peripheral vascular disease). • These patients can be educated on cholesterol, diet, exercise and the importance of a healthy lifestyle. • Patient empowerment and engagement in terms of their diagnosis and subsequent clinical management plan (NICE – patient participation is of importance regarding decision making in terms of drug therapy etc) <p>Predicted Benefits for NHS Organisations</p> <ul style="list-style-type: none"> • Reduce variation in identification and treatment of FH and primary hypercholesterolaemia and mixed dyslipidaemia across Leicestershire. • Assist PCNs in identifying and managing patients with cardiovascular disease in line with the NHS Long Term Plan • Supports implementation of NICE CG71. • Reduction in cardiovascular disease burden amongst Leicestershire patients will reduce associated hospital activity. <p>Predicted Benefits for Amgen</p> <ul style="list-style-type: none"> • The project aims to increase the FH, hypercholesterolaemia and mixed dyslipidaemia diagnosis rates. Patients diagnosed with these conditions will be treated with cholesterol lowering medicines in line with local / national guidelines and NICE TA 394. • Demonstrates collaborative working with the NHS to the benefit of patients and identifies scalable solutions. <p>The results of the project were written up to enable the learnings from the project to be shared.</p>
--	--